10-Q: Sera Prognostics Boosts Cash, Expands Commercial Team Amid Positive Clinical Data

Sera Prognostics reports a strengthened cash position and strategic commercial expansion, supported by positive clinical trial results for its PreTRM test, despite ongoing net losses.

Summary

• Net loss for the nine months ended September 30, 2025, was $24.0 million, a slight improvement from $24.3 million in the prior year period.
• Revenue for the nine months ended September 30, 2025, increased to $71 thousand from $53 thousand in the prior year period, though quarterly revenue decreased to $16 thousand from $29 thousand.
• Cash, cash equivalents, and marketable securities totaled $102.4 million as of September 30, 2025, significantly up from $68.2 million at December 31, 2024.
• The company completed an underwritten public offering in February 2025, raising approximately $53.6 million in net proceeds.
• Positive results from the AVERT PRETERM TRIAL (published July 2024) showed an 18% reduction in severe neonatal morbidity and mortality and a 7-day reduction in mean neonatal hospital length of stay.
• Key results from the PRIME study (presented January 2025) indicated a 25% reduction in neonatal morbidity and mortality and an 18% reduction in neonatal hospital length of stay in the modified intent-to-treat population.
• A meta-analysis of AVERT and PRIME studies demonstrated a pooled 22% decreased risk of prolonged hospital stay and a 22% reduction in neonatal morbidity and mortality.
• The company has begun expanding its commercial team, including hiring a Chief Commercial Officer in Q2 2025, field sales representatives in Q3 2025, and a Chief Medical Officer in October 2025.
• The office lease agreement was extended through June 30, 2034, with reduced leased space and a landlord contribution of $1.121 million for improvements, including a rent abatement for the first six months of 2026.
• The company believes its existing cash runway is sufficient to fund operations through 2028 based on current operating plans.

Sentiment

Score: 7

Explanation: The company shows strong progress in clinical validation and commercial strategy, backed by a significant capital raise that extends its cash runway. While still operating at a loss, the slight reduction in net loss and strategic investments in sales and marketing, coupled with favorable regulatory developments regarding LDTs, indicate a positive trajectory. The long-term profitability remains dependent on market adoption and reimbursement, but the current position is significantly improved.

Positives

• Net loss slightly decreased for both the three-month ($7.8M vs $7.9M) and nine-month ($24.0M vs $24.3M) periods ended September 30, 2025, compared to 2024.
• Total cash, cash equivalents, and marketable securities significantly increased to $102.4 million as of September 30, 2025, from $68.2 million at December 31, 2024, providing a strong liquidity position.
• The February 2025 public offering successfully raised approximately $53.6 million in net proceeds, extending the company's cash runway through 2028.
• Clinical trial results for the PreTRM test are highly positive, with the AVERT PRETERM TRIAL showing an 18% reduction in severe neonatal morbidity and mortality and the PRIME study demonstrating a 25% reduction in neonatal morbidity and mortality in the mITT population.
• A pooled meta-analysis of AVERT and PRIME studies further supports the PreTRM test's efficacy with a 22% reduction in neonatal morbidity and mortality and prolonged hospital stays.
• The American College of Obstetricians and Gynecologists (ACOG) updated its Clinical Consensus in May 2025, emphasizing risk assessments in prenatal care, which aligns with the PreTRM test's utility.
• Strategic expansion of the commercial team, including key hires like a Chief Commercial Officer and Chief Medical Officer, indicates a focused effort on market adoption.
• Research and development expenses decreased by $1.6 million for the nine months ended September 30, 2025, primarily due to winding down PRIME study costs, allowing for capital reallocation.
• The federal district court judge's decision in March 2025 to vacate the FDA's final rule on regulating Laboratory Developed Tests (LDTs) as medical devices, and the FDA's subsequent implementation of this vacatur in September 2025, temporarily alleviates a significant regulatory burden for the company's PreTRM test.

Negatives

• The company continues to incur significant operating losses, with an accumulated deficit of $303.8 million as of September 30, 2025.
• Revenue for the three months ended September 30, 2025, decreased to $16 thousand from $29 thousand in the prior year quarter.
• Selling and marketing expenses increased by $1.4 million for the nine months ended September 30, 2025, reflecting increased investment that may take several quarters to yield significant returns.
• The company relies heavily on the PreTRM test for substantially all its revenue, creating customer concentration risk, particularly with Elevance Health.
• Despite positive clinical data, widespread market adoption and favorable reimbursement from third-party payers for the PreTRM test remain uncertain and critical for future profitability.
• The company expects to incur significant additional operating losses and negative cash flows for the foreseeable future due to commercialization activities and pipeline development.

Risks

• Continued net losses and negative cash flows are anticipated for the foreseeable future, which could harm future business prospects.
• Operating the business requires significant cash, and the ability to generate sufficient cash depends on many factors, with no guarantee of raising additional capital when needed.
• Quarterly and annual results may fluctuate significantly, potentially impacting the Class A common stock value.
• Substantial reliance on the PreTRM test for revenue means failure to increase its use or develop new products would harm the business.
• Customer concentration risk exists due to reliance on a limited number of direct customers, including Elevance Health, for a significant portion of revenue.
• Inability to establish and maintain effective sales and marketing capabilities could hinder successful commercialization of the PreTRM test.
• Intense competition in the life science industry, particularly in molecular diagnostics and proteomics, poses a threat to revenue growth and profitability.
• The CLIA-certified laboratory facility becoming inoperable due to disasters or other events would prevent test performance and harm the business.
• Interim, top-line, and preliminary clinical trial data may change upon comprehensive review, audit, and verification, potentially leading to material changes in final data.
• Contamination, loss, or destruction of the proprietary biobank would materially harm the business.
• Loss of access to internal or external databases, which are heavily relied upon for products and services, could materially harm the business.
• Reliance on third parties for specimen collection and commercial courier delivery services means disruptions could harm the business.
• Reliance on a limited number of suppliers, or single suppliers, for laboratory instruments, materials, and collection kits creates supply chain risks.
• The ability to utilize net operating loss carryforwards and other tax attributes may be limited by ownership changes.
• Estimates of total addressable market opportunity and forecasts of market growth may prove inaccurate, and business growth may not match market growth.
• An inflationary environment and unstable global economic/geopolitical conditions could materially adversely impact business and results of operations.
• Inadequate funding for government agencies like the SEC could hinder their ability to perform normal business functions, impacting the company.
• Inadequate reimbursement from third-party payers for the PreTRM test or new products could limit purchases and adversely affect revenue and profits.
• New reimbursement methodologies, including CPT codes, may decrease reimbursement rates from third-party payers.
• Billing disputes with third-party payers, including disagreements over CPT codes, may decrease realized revenue and lead to recoupment requests.
• When third-party payers deny coverage, the company is often unable to collect from the patient or other sources, risking disputes.
• Withdrawal of coverage or lower reimbursement levels by third-party payers due to changing policies or billing complexities could adversely impact revenues.
• Status as an out-of-network provider with large commercial insurers may deter healthcare providers from recommending tests.
• Challenges to the validity of informed consent from patients could preclude billing, force cessation of tests, or lead to lawsuits.
• Changes in FDA regulation of reagents, consumables, and testing equipment could delay or increase expenses for bringing tests to market.
• Failure to comply with federal and/or state laboratory licensing requirements could result in loss of ability to perform tests or business disruptions.
• Failure to obtain, maintain, and enforce intellectual property rights could impair protection of proprietary technology and brand.
• Issued patents covering tests and technology could be found invalid or unenforceable if challenged.
• Intellectual property may be infringed by third parties, leading to costly and time-consuming litigation.
• Inability to prevent disclosure of trade secrets and other proprietary information could significantly diminish the value of tests and technology.
• The price of Class A common stock may be volatile, leading to potential loss of investment.
• Sales of a substantial number of shares by existing stockholders could cause the stock price to fall.
• The dual class structure of common stock may limit stockholders' ability to influence corporate matters.
• Reduced reporting requirements as an emerging growth company (EGC) and smaller reporting company may make Class A common stock less attractive to investors.
• Inability to maintain effective disclosure controls and procedures could adversely affect results, liquidity, financial positions, stock price, and investor confidence.
• Significant costs of operating as a public company and management time devoted to compliance initiatives.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reports or fraud.
• Public health threats, such as pandemics or epidemics, could materially affect operations and those of third parties.
• Employees or contractors engaging in conduct that violates healthcare laws could lead to substantial penalties and reputational damage.
• Headcount reductions undertaken to extend cash runway may not achieve intended outcomes and could result in unintended consequences.
• Engaging in acquisitions, dispositions, or other strategic transactions could disrupt business, cause dilution, or reduce financial resources.
• Artificial intelligence presents risks and challenges, including security risks to confidential information and potential liability from an uncertain regulatory environment.

Future Outlook

The company expects to continue incurring significant operating losses and negative cash flows for the foreseeable future, primarily due to commercialization activities for the PreTRM test and the development of other pipeline products. Research and development expenses are projected to decrease in 2026 as capital allocation shifts towards revenue-generating activities, while selling and marketing expenses are expected to increase in Q4 2025 and further in 2026 to support PreTRM commercialization. The company believes its existing cash and cash equivalents will fund operating expenses and capital requirements through 2028. Future funding requirements will depend on market adoption, regulatory approvals, and the success of new products, with potential needs for additional equity or debt financing.

Management Comments

• We believe our cash runway is sufficient to enable us to operate through 2028 based on our existing operating plans.
• We will continue to prudently monitor our operating expense levels.
• We will continue to pursue contracts with private and governmental payers and health systems using positive data from the PREVENT-PTB study, the AVERT PRETERM TRIAL, and the PRIME study, along with real-world evidence studies and other data we plan to generate.
• We expect that it may take a few quarters for each new sales representative to begin seeing significant density of adoption of this novel diagnostic test within their territory and to provide a favorable return on our commercial investment.
• Once we have proven this model is effective, we intend to add new geographies, further expand our commercial headcount, and increase sales and marketing investments to achieve meaningful PreTRM test adoption at scale.

Industry Context

The company operates in the women's health diagnostics industry, specifically focusing on proteomics and bioinformatics for maternal and neonatal health. The industry is characterized by rapid technological changes, intense competition, and significant reimbursement challenges. The company's PreTRM test addresses preterm birth, a major health risk with substantial economic consequences (estimated $25 billion annually in the U.S.). The recent vacatur of the FDA's LDT regulation rule provides temporary relief from a potentially burdensome regulatory shift, aligning with the industry's ongoing push for a harmonized legislative solution for LDT oversight. The emphasis by ACOG on risk assessments in prenatal care provides a favorable backdrop for the adoption of the PreTRM test, positioning the company within a broader trend towards personalized and risk-stratified healthcare.

Comparison to Industry Standards

• The PreTRM test's reported Number Needed to Screen (NNS) to save a NICU day is about 3-4, and to save a NICU admission is 41. This compares favorably to the standard of care for short cervix (transvaginal ultrasound plus progesterone treatments), which has an NNS to save a NICU admission of 150, indicating superior efficiency in identifying and impacting outcomes for high-risk pregnancies.
• The company's clinical trial results, including an 18% reduction in severe neonatal morbidity and mortality (AVERT PRETERM TRIAL) and a 25% reduction in neonatal morbidity and mortality (PRIME study mITT population), demonstrate significant clinical utility compared to existing methods for predicting adverse pregnancy outcomes, which are deemed insufficient for timely and effective proactive management for the majority of high-risk pregnancies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material litigation or other material legal proceedings.
• A federal district court judge issued a decision in March 2025 that vacated the FDA's final rule to regulate Laboratory Developed Tests (LDTs) under the existing medical device framework. The FDA formally implemented this vacatur in September 2025, meaning the company will not become subject to these medical device regulatory requirements as previously expected. This is a significant regulatory development impacting the company's operating environment.

Related Party Transactions

• The company has a Commercial Collaboration Agreement with Elevance Health and its affiliates, which includes a Laboratory Services Agreement with Carelon Research (a subsidiary of Elevance Health) for the PRIME study.
• Payments to Carelon Research for research and development expenses were $0.2 million for the three months and $0.5 million for the nine months ended September 30, 2025.
• No material revenues were recognized from the Commercial Collaboration Agreement for the three and nine months ended September 30, 2025.
• In the February 2025 public offering, entities affiliated with one of the company's principal stockholders purchased pre-funded warrants to acquire up to 11,250,000 shares of Class A common stock.
• Another principal stockholder purchased 625,000 shares of Class A common stock in the same public offering.

Stakeholder Impact

• **Shareholders**: The successful capital raise and extended cash runway through 2028 reduce immediate dilution risk and provide stability, but continued operating losses and potential future capital needs could lead to further dilution. Positive clinical data and commercial expansion efforts aim to drive long-term value.
• **Employees**: Strategic hiring in commercial and medical roles indicates growth opportunities, but past headcount reductions highlight a focus on cost efficiency and potential for future organizational changes.
• **Customers (Healthcare Providers & Patients)**: Positive clinical trial results for the PreTRM test offer a validated tool to improve maternal and neonatal health outcomes, potentially leading to better patient care. Expanded commercial efforts aim to increase access to the test.
• **Payer/Creditors**: The strengthened cash position and extended cash runway improve the company's financial stability and ability to meet obligations. Successful market adoption and reimbursement are crucial for long-term revenue generation to satisfy payers and creditors.
• **Suppliers**: Reliance on a limited number of suppliers for key components poses supply chain risks, which could impact the company's ability to perform tests and generate revenue.

Next Steps

• Seek publication of full PRIME study data in a highly respected, peer-reviewed journal.
• Generate additional publications on exploratory analyses and economic benefits from the PRIME study.
• Integrate data from studies into a health economic model to demonstrate potential economic value to prospective customers.
• Complete the qualitative pre-implementation phase of the first real-world evidence implementation study.
• Add new geographies and further expand commercial headcount and sales and marketing investments once the current commercial model proves effective.
• Actively discover and develop additional biomarker and predictive analytics tests for other major conditions of pregnancy.
• Continue market testing of the delivery date estimation product in selected geographies in the United States.
• Continue to pursue contracts with private and governmental payers and health systems using positive clinical and real-world evidence data.

Key Dates

Recommendation

Sera Prognostics has demonstrated significant progress with strong clinical data for its PreTRM test and has substantially improved its liquidity through a recent public offering, extending its cash runway through 2028. This provides a solid foundation for continued commercialization efforts and pipeline development. However, the company remains pre-profitability, with ongoing net losses and the need for substantial market adoption and favorable reimbursement to achieve sustained revenue growth. While the regulatory landscape for LDTs has seen a favorable turn, long-term regulatory certainty is still evolving. The strategic investments in sales and marketing are positive, but their return on investment will take time to materialize. Given the strong clinical evidence and improved financial stability, but balanced against the inherent risks of a pre-profit, growth-stage diagnostics company, a 'hold' recommendation is appropriate for investors to monitor the execution of its commercial strategy and progress towards profitability.

Keywords

PreTRM test, preterm birth, proteomics, bioinformatics, maternal health, neonatal health, diagnostic tests, clinical trials, AVERT PRETERM TRIAL, PRIME study, SEC filing, 10-Q, financial results, cash runway, public offering, commercialization, healthcare, biomarker, risk assessment, CLIA-certified laboratory, FDA regulation, LDTs, intellectual property, corporate governance